BackBellevue Life Sciences Acquisition - Warrants (09/02/2028) Overview

Bellevue Life Sciences Acquisition - Warrants (09/02/2028) Current Cash

Track Bellevue Life Sciences Acquisition - Warrants (09/02/2028)'s current cash ($1.6M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$1.57M
1.82% YoYΔ $-28996.00 vs prior year quarter

Peer average

Loading

Bellevue Life Sciences Acquisition - Warrants (09/02/2028) Current Cash History

Loading

Bellevue Life Sciences Acquisition - Warrants (09/02/2028) vs. peers: Current Cash Comparison

Loading

Bellevue Life Sciences Acquisition - Warrants (09/02/2028) Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bellevue Life Sciences Acquisition - Warrants (09/02/2028) (BLACW) FAQ

The latest current cash for BLACW is $1.6M as of March 2026. That compares with $1.6M in the prior-year period — down 1.8% year over year. Investors often review this figure alongside Bellevue Life Sciences Acquisition - Warrants (09/02/2028)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, BLACW's current cash moved from $1.6M to $1.6M — a 1.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bellevue Life Sciences Acquisition - Warrants (09/02/2028)'s operating scale or balance-sheet position.

A current cash figure of $1.6M for BLACW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BLACW's current cash ($1.6M), review year-over-year change from $1.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.